Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Camp4 TherapeuticsCAMP +0.67%8 Cash Ratio is 4.51 as of Jun. 2026, which is 24% below its 10-year median of 5.97. GuruFocus rates CAMP with a GF Score™ of 8/100. The stock has 4 warning signs investors should review. Among 1,355 Biotechnology companies, Camp4 Therapeutics ranks better than 60.66% on this metric.
Camp4 Therapeutics has a Cash Ratio of 4.51. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Camp4 Therapeutics's Cash Ratio or its related term are showing as below:
CAMP'
s Cash Ratio Range Over the Past 10 Years
Min: 0.21 Med: 5.97 Max: 10.47
Current: 4.51
During the past 4 years, Camp4 Therapeutics's highest Cash Ratio was 10.47. The lowest was 0.21. And the median was 5.97.
CAMP's Cash Ratio is ranked better than 60.66% of 1355
companies
in the Biotechnology industry
Industry Median: 2.96
vs CAMP: 4.51
Camp4 Therapeutics (NAS:CAMP) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Camp4 Therapeutics Cash Ratio Related Terms
Camp4 Therapeutics Cash Ratio Historical Data
* Premium members only.
The historical data trend for Camp4 Therapeutics's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Camp4 Therapeutics's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Camp4 Therapeutics Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Camp4 Therapeutics's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Camp4 Therapeutics's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Camp4 Therapeutics (CAMP) has a Cash Ratio of 4.51 as of Jun. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Camp4 Therapeutics and its competitors. This is 24% below median its historical median of 5.97. Over the past decade, Camp4 Therapeutics' Cash Ratio has ranged from 0.21 to 10.47. According to the industry distribution chart, Camp4 Therapeutics ranks #533 out of 1355 companies in the Biotechnology industry, placing it in the top 39.3%.
Is Camp4 Therapeutics' Cash Ratio too high?
Camp4 Therapeutics' current Cash Ratio of 4.51 is 24% below median its 10-year median of 5.97. Over the past 10 years, this metric has ranged from a low of 0.21 to a high of 10.47. The Biotechnology industry median Cash Ratio is 2.96. Camp4 Therapeutics' value of 4.51 is 52.4% above this industry median. Based on the distribution chart, Camp4 Therapeutics ranks #533 out of 1355 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Camp4 Therapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Camp4 Therapeutics' Cash Ratio compare to ALEC and ORMP?
According to the Biotechnology industry distribution chart, Camp4 Therapeutics ranks #533 out of 1355 companies for Cash Ratio. This puts Camp4 Therapeutics in the upper half of its industry. The industry median Cash Ratio is 2.96. Camp4 Therapeutics' value of 4.51 is 52.4% above this benchmark. Historically, Camp4 Therapeutics' own Cash Ratio has ranged from 0.21 to 10.47 over the past decade. While the company's 10-year median is 5.97 vs. the industry median of 2.96, Camp4 Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.96, based on 1,355 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Camp4 Therapeutics's current Cash Ratio of 4.51 is 52.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Camp4 Therapeutics and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Camp4 Therapeutics's current Cash Ratio is 4.51, which is 24% below median its own 10-year median of 5.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Camp4 Therapeutics stock overvalued right now?
Camp4 Therapeutics (CAMP) has a current Cash Ratio of 4.51. The current Cash Ratio is 4.51, which is 24% below median its 10-year median of 5.97 and 52.4% above the Biotechnology industry median of 2.96. Camp4 Therapeutics' overall GF Score™ is 8/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Camp4 Therapeutics (CAMP), the current Cash Ratio is 4.51 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Camp4 Therapeutics Corp is a clinical-stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics to upregulate gene expression and restore healthy protein levels to treat various genetic diseases. The company focuses on genetic diseases of the central nervous system and liver. Its pipeline products include CMP-CPS-001 and CMP-SYNGAP. The company operates as a single operating segment, R&D, which engages in the development of a new class of RNA-based therapeutics to treat a broad range of genetic diseases.
8GF Score
Get the complete analysis for CAMP
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAMP has been successfully added to your 
